BRCA Mutations Treatment Market Players:
- Roche Holding AG
- Company Overview
- Business Planning
- Main Product Offerings
- Financial Execution
- Main Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Celgene
- Bristol-Myers Squibb Company
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
- AstraZeneca
- Merck & Co., Inc.
- Novartis AG
- AbbVie Inc.
- Astellas Pharma Inc.
A number of end-use companies are available that deal with BRCA mutation treatment. Here are some majorities of key players;
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of BRCA mutations treatment is assessed at USD 5.1 million.
The global BRCA mutations treatment market size surpassed USD 4.85 million in 2025 and is projected to witness a CAGR of over 5.8%, crossing USD 8.52 million revenue by 2035.
North America is set to capture around 39% share by 2035 in the BRCA mutations treatment market, observed owing to the increasing advancement in technology for the treatment of cancer in the region.
Key players in the market include Roche Holding AG, Celgene, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc., AstraZeneca, Merck & Co., Inc., Novartis AG, AbbVie Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company, Otsuka Holdings Co Ltd, Eisai Co Ltd, Shionogi & Co Ltd.
